Corporate News
CVC Capital Partners Plc is reportedly evaluating the sale of its Chinese retail pharmacy chain, Yikang Pharmaceutical. According to sources familiar with the matter, the private‑equity firm is working with advisers to assess a potential transaction. Yikang, which was founded in 2001 and operates more than 1,700 outlets across China, has been under CVC’s ownership since a full buyout in 2023 following an initial investment in 2021.
The company’s business model combines online‑to‑offline and direct‑to‑patient services, and it serves a large membership base through its pharmacy network. While the firm has not yet reached a definitive decision, preliminary discussions suggest that the valuation for a sale could fall within a range that reflects substantial market interest.
The announcement has prompted attention from investors and analysts monitoring private‑equity activity in the Chinese healthcare sector, though CVC has declined to comment publicly and the chain has not issued a statement. The potential sale represents a significant development for CVC, which has been active in acquiring and consolidating assets within emerging markets. The outcome of these negotiations may influence future investment strategies in the region’s pharmaceutical retail space.
